Jaguar Health Inc JAGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
-
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
-
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
-
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
-
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
-
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
-
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
-
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Trading Information
- Previous Close Price
- $1.27
- Day Range
- $1.24–1.27
- 52-Week Range
- $1.03–91.00
- Bid/Ask
- $0.97 / $1.40
- Shares Outstanding
- 4.91M
- Market Cap
- $6.14M
- Volume/Avg
- 35,016 / 99,107
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 47
- Website
- http://www.jaguar.health
Valuation
|
Metric
|
JAGX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.00 |
Price/Cash Flow | — |
Price/Earnings
JAGX
Financial Strength
|
Metric
|
JAGX
|
|---|---|
Quick Ratio | 0.19 |
Current Ratio | 0.50 |
Interest Coverage | −41.19 |
Quick Ratio
JAGX
Profitability
|
Metric
|
JAGX
|
|---|---|
Return on Assets (Normalized) | −45.00% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −58.58% |
Return on Assets
JAGX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|B$HRpJN | LOCK|V^C%t | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$K?!m^Y | LOCK|?NJ#c | $71B | |||
| argenx SE ADR
ARGX
| LOCK|yrnq>!% | LOCK|bD | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#D^>s@ | LOCK|$$ | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Bbx@V&z | LOCK|vfB$ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|vHmlPz^ | LOCK|^YkyH | $26B | |||
| Moderna Inc
MRNA
| LOCK|^F&MWH | LOCK|lR | $25B | |||
| Incyte Corp
INCY
| LOCK|nD@nDK@ | LOCK|xg | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|khgZn? | LOCK|bZ^ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|XcX<V#^ | LOCK|%%@ | $16B |
United States